发明名称 Uso de ésteres de ácidos amidoximo-carboxílicos e de ésteres de ácidos n-hidroxiguanidino-carboxílicos para a produção de prodrogas
摘要 Use of amidoxime carboxylic acid ester compound (I) or N-hydroxyguanidine carboxylic acid ester compound (II), as substitution of amidine-, N-hydroxyamidine- (amidoxime), guanidine- or N-hydroxyguanidine-functions of an active agent in a medicament to improve the solubility, bioavailability and/or blood-brain-barrier mobility of the medicament, is claimed, where the active agent is protease inhibitor, an inhibitor of factor Xa, factor VII or all protease of the coagulation cascade or a matriptase inhibitor, DNA- and RNA-intercalating compounds, or the N-methyl-D-aspartate-receptor-antagonist. Use of amidoxime carboxylic acid ester compound of formula (CH 3-C(NH 2)=N-O-C(=O)-(CH 2) n-C(=O)-OR 1) (I) or N-hydroxyguanidine carboxylic acid ester compound of formula (CH 3-NH-C(NH 2)=N-O-C(=O)-(CH 2) n-C(=O)-OR 1) (II), as substitution of amidine-, N-hydroxyamidine- (amidoxime), guanidine- or N-hydroxyguanidine-functions of an active agent in a medicament to improve the solubility, bioavailability and/or blood-brain-barrier mobility of the medicament, is claimed, where the active agent is protease inhibitor, preferably a thrombin inhibitor, an inhibitor of a factor Xa, factor VII, all protease of the coagulation cascade or a matriptase inhibitor, DNA- and RNA-intercalating compounds, inhibitor of viral enzyme or the N-methyl-D-aspartate-receptor-antagonist. R 1 : H, alkyl, or aryl or its salt; and n : 0-12. ACTIVITY : Protozoacide; Antiinflammatory; Respiratory-Gen.; Cytostatic; Anticoagulant; Thrombolytic; Hemostatic; Hypertensive; Neuroprotective; Virucide; Anti-HIV. MECHANISM OF ACTION : None given.
申请公布号 BRPI0906569(A2) 申请公布日期 2015.07.07
申请号 BR2009PI06569 申请日期 2009.02.02
申请人 DRITTE PATENTPORTFOLIO BETEILIGUNGSGESELLSCHAFT MBH & CO. KG 发明人 BERND CLEMENT;CHRISTIANE REEH;HELEN HUNGELING
分类号 A61K31/155;A61P7/02;A61P9/12;A61P25/28;A61P31/16;A61P31/18;A61P33/02;A61P35/00 主分类号 A61K31/155
代理机构 代理人
主权项
地址